Weight Loss Peptides Explained: Semaglutide, Tirzepatide, and Retatrutide Compared

Peptide-based medications have transformed the conversation around weight management over the past few years. Terms like peptide, semaglutide, tirzepatide, and retatrutide now show up everywhere from doctor's offices to social media feeds. But what are these drugs actually doing in the body, how do they differ, and what should you know before considering one? This guide breaks it all down.

What Are Weight Loss Peptides?

A peptide is simply a short chain of amino acids — the same building blocks that make up proteins, just smaller. Many hormones in the human body are peptides, including the ones that regulate appetite, blood sugar, and digestion. Weight loss peptide drugs are synthetic versions of these natural hormones (or close mimics of them), engineered to last longer in the bloodstream so they can be injected weekly instead of needing to be replaced constantly like the natural hormone.

The three peptides getting the most attention right now — semaglutide, tirzepatide, and retatrutide — all work by imitating gut hormones that signal fullness to the brain and help regulate blood sugar. The differences between them come down to how many of these hormone pathways each drug targets.

Semaglutide: The Original Breakthrough

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a single natural hormone, GLP-1, which:

Slows down how quickly the stomach empties, so you feel full longer
Reduces appetite signals in the brain
Helps the pancreas release insulin more efficiently

Semaglutide is sold under the brand names Wegovy (for weight management) and Ozempic (for type 2 diabetes), and it's also now available in an oral tablet form. In clinical trials, people using semaglutide for weight loss have lost around 15% of their body weight on average over roughly a year of treatment.

Tirzepatide: A Dual-Action Peptide

Tirzepatide takes the concept a step further. It's a dual GIP/GLP-1 receptor agonist, meaning it activates two hormone pathways instead of one — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP plays an additional role in fat metabolism and insulin sensitivity.

Sold as Zepbound (weight management) and Mounjaro (type 2 diabetes), tirzepatide has produced greater average weight loss in trials than semaglutide — commonly in the 20-22% range of body weight — which has made it a popular next step for people who plateau on single-pathway medications.

Retatrutide: The Investigational Triple Agonist

Retatrutide is the newest and most talked-about peptide in this category. It's a triple agonist, activating GLP-1, GIP, and glucagon receptors simultaneously. That third pathway, glucagon, is thought to help the body burn additional fat rather than only suppressing appetite.

As of mid-2026, retatrutide has delivered the strongest weight loss results of any peptide in this class in clinical trials, with some studies reporting average reductions of around 20-30% of body weight over roughly a year and a half.

Importantly, retatrutide is not yet FDA approved. It remains in late-stage Phase 3 clinical trials. Manufacturer Eli Lilly has indicated it plans to file for approval in late 2026, with the earliest realistic approval and market launch expected in 2027-2028. Until then, the only legitimate way to access retatrutide is by enrolling in an authorized clinical trial. It is not legally available by prescription, and products sold as "research-grade retatrutide" online are unregulated, unverified, and carry real safety risks — they should be avoided.

Common Side Effects

All three peptides work on similar digestive and metabolic pathways, so they tend to share a similar side effect profile, especially early in treatment or when doses increase:

Nausea
Diarrhea or constipation
Vomiting
Fatigue
Injection site reactions

Side effects are generally most noticeable during dose escalation and tend to ease over time. Because retatrutide activates an additional pathway, some trial data suggests a somewhat higher rate of gastrointestinal side effects and discontinuation compared to semaglutide, though results vary by study and dose.

Are These Peptides Right for You?

Weight loss peptides are prescription medications intended for people who meet specific medical criteria, typically a BMI at or above 30 (or 27 with a weight-related health condition), and they work best alongside diet and lifestyle changes, not as a replacement for them. They also carry contraindications — for example, they're generally not recommended for people with a personal or family history of certain thyroid cancers.

If you're considering a GLP-1, dual, or triple-agonist peptide for weight loss, the right first step is a conversation with a licensed healthcare provider who can review your medical history, discuss which option fits your situation, and monitor you throughout treatment. This article is for general educational purposes and isn't a substitute for personalized medical advice.

The Bottom Line

Peptide medications have moved from niche diabetes drugs to some of the most effective weight management tools available. Semaglutide opened the door, tirzepatide expanded on it with a second hormone pathway, and retatrutide — still investigational — is pushing the boundaries further with a third. As more triple- and multi-agonist peptides move through clinical trials, this is likely to remain one of the fastest-evolving areas in modern medicine.
https://genetexpharma.com/